Thyroid cancer incidence is increasing throughout the world. Although this appears to be due largely to enhanced detection of early thyroid cancers by the more generalised use of thyroid ultrasound ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the ...

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...

The US FDA’s approval is based on data from the ongoing Phase 2 PHAROS clinical trial (NCT03915951), an open-label, multicenter, single-arm study examining BRAFTOVI+MEKTOVI combination therapy in both ...

A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...

Researchers have discovered a signaling pathway between cytokines and BRAF that promotes tumor growth. The finding could provide a potential therapeutic target. The protein BRAF is a key player in the ...

LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...

Please provide your email address to receive an email when new articles are posted on . The triplet combination of vemurafenib/cobimetinib/atezolizumab showed ...

Results from the Phase II PHAROS trial found that treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer administered Braftovi in combination with Mektovi achieved an ...

In patients with skin or lung cancer, drugs that inhibit BRAF (v-raf murine sarcoma viral oncogene homolog B) mutations increase the risk for uveitis dramatically compared with conventional ...